Health Care • Biotechnology: Pharmaceutical Preparations
$72.00 ▼ -1.16
(-1.59%)
MKT CAP: $1.68B • VOL: 286.9K
52W L $70 52W H $96
ANIP // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $883.4M | $614.4M | $486.8M |
| YoY Revenue Growth % | +43.8% | +26.2% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $111.1M | $584.0K | $47.0M |
| Operating Margin % | 12.6% | 0.1% | 9.6% |
| Net Income (GAAP) | $78.0M | -$19.0M | $19.0M |
| EBITDA (Normalized) | $122.2M | $13.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $185.2M | $64.0M | $119.0M |
| Capital Expenditures (CapEx) | $13.8M | $16.2M | — |
| Free Cash Flow (FCF) | $171.4M | $47.8M | $119.0M |
| FCF Margin % | 19.4% | 7.8% | 24.4% |
| Return on Invested Capital (ROIC %) | 16.0% | 0.1% | — |
| Cash & Short-Term Equivalents | $285.6M | $144.9M | — |
| Total Debt (Short + Long Term) | $291.8M | $309.1M | — |
| Total Stockholders' Equity | $540.7M | $403.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ANIP.